Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Anchorage Radiation Therapy Center — Anchorage, Alaska
+ 952 more sites in the U.S.
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Locations: - Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- Mercy Hospital Fort Smith — Fort Smith, Arkansas
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
+ 378 more sites in the U.S.
Phase 3 Recruiting Industry
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06393374
Locations: - Infirmary Cancer Care ( Site 0001) — Mobile, Alabama
- Ironwood Cancer & Research Centers-Research ( Site 0054) — Chandler, Arizona
- MemorialCare Orange Coast Medical Center ( Site 9501) — Fountain Valley, California
+ 90 more sites in the U.S.
Phase 3 Recruiting Industry
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metasta…
Sponsor: BriaCell Therapeutics Corporation
NCT ID: NCT06072612
Locations: - Mayo Clinic-Comprehensive Cancer Center-Breast Clinic — Phoenix, Arizona
- University of Arizona-Cancer Center — Tucson, Arizona
- Los Angeles cancer Network_Anaheim — Anaheim, California
+ 76 more sites in the U.S.
Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…
Sponsor: AstraZeneca
NCT ID: NCT06103864
Locations: - Research Site — Daphne, Alabama
- Research Site — Springdale, Arkansas
- Research Site — Duarte, California
+ 64 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to investigate the efficacy and safety of BGB-43395 in combination with letrozole compared with investigator's choice of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in combination with letrozole in patients…
Sponsor: BeOne Medicines
NCT ID: NCT07492641
Locations: - Alabama Oncology Princeton — Birmingham, Alabama
- Alaska Oncology and Hematology, Llc — Anchorage, Alaska
- Fairbanks Cancer Care Physicians Pc — Fairbanks, Alaska
+ 60 more sites in the U.S.
Phase 3 Recruiting Industry
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+,…
Sponsor: AstraZeneca
NCT ID: NCT06380751
Locations: - Research Site — Gilbert, Arizona
- Research Site — Fountain Valley, California
- Research Site — Glendale, California
+ 57 more sites in the U.S.
Phase 3 Recruiting Industry
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…
Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT06982521
Locations: - Banner MD Anderson Cancer Center — Gilbert, Arizona
- Beverly Hills Cancer Center — Beverly Hills, California
- City of Hope National Medical Center — Duarte, California
+ 49 more sites in the U.S.
Phase 3 Recruiting Industry
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metasta…
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06435429
Locations: - Mayo Clinic Scottsdale - PPDS — Phoenix, Arizona
- Arizona Oncology Tucson - Wilmot — Tucson, Arizona
- University of Arizona Cancer Center — Tucson, Arizona
+ 45 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Locations: - Local Institution - 0303 — Hot Springs, Arkansas
- Helios Clinical Research — Cerritos, California
- Local Institution - 0307 — Cerritos, California
+ 43 more sites in the U.S.
Phase 3 Recruiting Industry
This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor (HR)-positive, hu…
Sponsor: Hoffmann-La Roche
NCT ID: NCT05646862
Locations: - Marin Cancer Care Inc — Greenbrae, California
- Cancer Blood and Specialty Clinic — Los Alamitos, California
- Los Angeles Cancer Network — Los Angeles, California
+ 36 more sites in the U.S.
Phase 3 Recruiting Network
The purpose of this research study is to learn more about the effects of using proton radiation therapy delivered over a shorter course of treatment (3 weeks) compared with a longer, standard course of treatment (5 weeks) for women with br…
Sponsor: Proton Collaborative Group
NCT ID: NCT05856773
Locations: - Mayo Clinic — Scottsdale, Arizona
- California Protons Cancer Therapy Center — San Diego, California
- University of Florida Proton Therapy Institute — Jacksonville, Florida
+ 6 more sites in the U.S.